Cremolini C, Antoniotti C, Stein A, et al. - Researchers aimed at determining the overall survival (OS) benefit from infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab vs doublets + bevacizumab. In addition, they examined the interaction of treatment effect with main patient and disease characteristics. For this individual patient data (IPD) meta-analysis, they retrieved IPD from five eligible trials: CHARTA, OLIVIA, STEAM, TRIBE, and TRIBE2. Random assignment of 1,697 patients to receive FOLFOXIRI + bevacizumab (n = 846) or doublets + bevacizumab (n = 851) was done. An Eastern Cooperative Oncology Group performance status of 0 was reported in most (78%) patients; the median age was 61 years. Patients with metastatic colorectal cancer showed significant improvement in survival and benefited in terms of PFS, ORR, and R0 resection rate in correlation with receiving FOLFOXIRI + bevacizumab vs doublets + bevacizumab, though with a moderate increase in toxicity. Patients with BRAF-mutant tumors showed no increased benefit.